Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Consun Pharmaceutical Group Ltd. ( (HK:1681) ) is now available.
Consun Pharmaceutical Group Limited has expanded its existing share repurchase initiative, authorising an additional HKD100 million in buybacks under its current mandate, bringing the total potential repurchase scale to up to HKD300 million, or no more than 10% of its issued share capital, to be executed in the open market up to the next annual general meeting. Management says the move reflects confidence in the company’s fundamentals and believes the stock is undervalued, aiming to optimise capital structure and enhance per-share metrics while funding the repurchases from existing cash resources, though the timing and volume of any actual buybacks will depend on market conditions and remain at the company’s discretion.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$20.50 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company focused on the research, development, manufacture and sale of pharmaceutical products. The group operates through multiple subsidiaries and targets growth in the broader healthcare market, leveraging its capital structure to support ongoing business expansion and long-term development.
Average Trading Volume: 1,737,529
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.62B
Learn more about 1681 stock on TipRanks’ Stock Analysis page.